Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Global Cerebral Atrophy Detected by Routine Imaging: Relationship with Age, Hippocampal Atrophy, and White Matter Hyperintensities.

Al-Janabi OM, Panuganti P, Abner EL, Bahrani AA, Murphy R, Bardach SH, Caban-Holt A, Nelson PT, Gold BT, Smith CD, Wilcock DM, Jicha GA.

J Neuroimaging. 2018 May;28(3):301-306. doi: 10.1111/jon.12494. Epub 2018 Jan 5.

PMID:
29314393
2.

An emerging role of astrocytes in vascular contributions to cognitive impairment and dementia.

Price BR, Norris CM, Sompol P, Wilcock DM.

J Neurochem. 2018 Mar;144(5):644-650. doi: 10.1111/jnc.14273. Epub 2018 Jan 22. Review.

PMID:
29222909
3.

Hyperhomocysteinemia-Induced Gene Expression Changes in the Cell Types of the Brain.

Weekman EM, Woolums AE, Sudduth TL, Wilcock DM.

ASN Neuro. 2017 Nov-Dec;9(6):1759091417742296. doi: 10.1177/1759091417742296.

4.

The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases.

Nelson PT, Abner EL, Patel E, Anderson S, Wilcock DM, Kryscio RJ, Van Eldik LJ, Jicha GA, Gal Z, Nelson RS, Nelson BG, Gal J, Azam MT, Fardo DW, Cykowski MD.

J Neuropathol Exp Neurol. 2018 Jan 1;77(1):2-20. doi: 10.1093/jnen/nlx099. Review.

PMID:
29186501
5.

Specific Immunoglobulin (Ig) G Reference Intervals for Common Food, Insect, and Mold Allergens.

Martins TB, Bandhauer ME, Wilcock DM, Hill HR, Slev PR.

Ann Clin Lab Sci. 2016 Dec;46(6):635-638.

PMID:
27993877
6.

Time-course of glial changes in the hyperhomocysteinemia model of vascular cognitive impairment and dementia (VCID).

Sudduth TL, Weekman EM, Price BR, Gooch JL, Woolums A, Norris CM, Wilcock DM.

Neuroscience. 2017 Jan 26;341:42-51. doi: 10.1016/j.neuroscience.2016.11.024. Epub 2016 Nov 25.

7.

Aβ vaccination in combination with behavioral enrichment in aged beagles: effects on cognition, Aβ, and microhemorrhages.

Davis PR, Giannini G, Rudolph K, Calloway N, Royer CM, Beckett TL, Murphy MP, Bresch F, Pagani D, Platt T, Wang X, Donovan AS, Sudduth TL, Lou W, Abner E, Kryscio R, Wilcock DM, Barrett EG, Head E.

Neurobiol Aging. 2017 Jan;49:86-99. doi: 10.1016/j.neurobiolaging.2016.09.007. Epub 2016 Sep 26.

8.

Reduced Efficacy of Anti-Aβ Immunotherapy in a Mouse Model of Amyloid Deposition and Vascular Cognitive Impairment Comorbidity.

Weekman EM, Sudduth TL, Caverly CN, Kopper TJ, Phillips OW, Powell DK, Wilcock DM.

J Neurosci. 2016 Sep 21;36(38):9896-907. doi: 10.1523/JNEUROSCI.1762-16.2016.

9.

(1)H-MRS metabolites in adults with Down syndrome: Effects of dementia.

Lin AL, Powell D, Caban-Holt A, Jicha G, Robertson W, Gold BT, Davis R, Abner E, Wilcock DM, Schmitt FA, Head E.

Neuroimage Clin. 2016 Jun 2;11:728-35. doi: 10.1016/j.nicl.2016.06.001. eCollection 2016.

10.

Vascular Contributions to Cognitive Impairment and Dementia: Topical Review of Animal Models.

Madigan JB, Wilcock DM, Hainsworth AH.

Stroke. 2016 Jul;47(7):1953-9. doi: 10.1161/STROKEAHA.116.012066. Epub 2016 Jun 14. No abstract available.

11.

The roles of inflammation and immune mechanisms in Alzheimer's disease.

Van Eldik LJ, Carrillo MC, Cole PE, Feuerbach D, Greenberg BD, Hendrix JA, Kennedy M, Kozauer N, Margolin RA, Molinuevo JL, Mueller R, Ransohoff RM, Wilcock DM, Bain L, Bales K.

Alzheimers Dement (N Y). 2016 May 30;2(2):99-109. doi: 10.1016/j.trci.2016.05.001. eCollection 2016 Jun. Review.

12.

Calcineurin proteolysis in astrocytes: Implications for impaired synaptic function.

Pleiss MM, Sompol P, Kraner SD, Abdul HM, Furman JL, Guttmann RP, Wilcock DM, Nelson PT, Norris CM.

Biochim Biophys Acta. 2016 Sep;1862(9):1521-32. doi: 10.1016/j.bbadis.2016.05.007. Epub 2016 May 20.

13.

Animal Models of Vascular Cognitive Impairment and Dementia (VCID).

Gooch J, Wilcock DM.

Cell Mol Neurobiol. 2016 Mar;36(2):233-9. doi: 10.1007/s10571-015-0286-3. Epub 2016 Mar 17. Review.

PMID:
26988696
14.

Vascular contributions to cognitive impairment and dementia (VCID).

Murphy MP, Corriveau RA, Wilcock DM.

Biochim Biophys Acta. 2016 May;1862(5):857-9. doi: 10.1016/j.bbadis.2016.02.010. Epub 2016 Feb 26. No abstract available.

15.

Homocysteine, hyperhomocysteinemia and vascular contributions to cognitive impairment and dementia (VCID).

Hainsworth AH, Yeo NE, Weekman EM, Wilcock DM.

Biochim Biophys Acta. 2016 May;1862(5):1008-17. doi: 10.1016/j.bbadis.2015.11.015. Epub 2015 Dec 9.

16.

Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Head E, Lott IT, Wilcock DM, Lemere CA.

Curr Alzheimer Res. 2016;13(1):18-29. Review.

17.

Matrix Metalloproteinase in Blood-Brain Barrier Breakdown in Dementia.

Weekman EM, Wilcock DM.

J Alzheimers Dis. 2016;49(4):893-903. doi: 10.3233/JAD-150759. Review.

PMID:
26599057
18.

Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome.

Wilcock DM, Schmitt FA, Head E.

Biochim Biophys Acta. 2016 May;1862(5):909-14. doi: 10.1016/j.bbadis.2015.11.007. Epub 2015 Nov 26.

19.

Down syndrome individuals with Alzheimer's disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer's disease.

Wilcock DM, Hurban J, Helman AM, Sudduth TL, McCarty KL, Beckett TL, Ferrell JC, Murphy MP, Abner EL, Schmitt FA, Head E.

Neurobiol Aging. 2015 Sep;36(9):2468-74. doi: 10.1016/j.neurobiolaging.2015.05.016. Epub 2015 May 30.

20.

Determining the role of IL-4 induced neuroinflammation in microglial activity and amyloid-β using BV2 microglial cells and APP/PS1 transgenic mice.

Latta CH, Sudduth TL, Weekman EM, Brothers HM, Abner EL, Popa GJ, Mendenhall MD, Gonzalez-Oregon F, Braun K, Wilcock DM.

J Neuroinflammation. 2015 Mar 4;12:41. doi: 10.1186/s12974-015-0243-6.

21.

Vascular contributions to cognitive impairment and dementia including Alzheimer's disease.

Snyder HM, Corriveau RA, Craft S, Faber JE, Greenberg SM, Knopman D, Lamb BT, Montine TJ, Nedergaard M, Schaffer CB, Schneider JA, Wellington C, Wilcock DM, Zipfel GJ, Zlokovic B, Bain LJ, Bosetti F, Galis ZS, Koroshetz W, Carrillo MC.

Alzheimers Dement. 2015 Jun;11(6):710-7. doi: 10.1016/j.jalz.2014.10.008. Epub 2014 Dec 12. Review.

22.

Neuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapy.

Latta CH, Brothers HM, Wilcock DM.

Neuroscience. 2015 Aug 27;302:103-11. doi: 10.1016/j.neuroscience.2014.09.061. Epub 2014 Oct 5. Review.

23.

Transition from an M1 to a mixed neuroinflammatory phenotype increases amyloid deposition in APP/PS1 transgenic mice.

Weekman EM, Sudduth TL, Abner EL, Popa GJ, Mendenhall MD, Brothers HM, Braun K, Greenstein A, Wilcock DM.

J Neuroinflammation. 2014 Jul 25;11:127. doi: 10.1186/1742-2094-11-127.

24.

mNos2 deletion and human NOS2 replacement in Alzheimer disease models.

Colton CA, Wilson JG, Everhart A, Wilcock DM, Puoliväli J, Heikkinen T, Oksman J, Jääskeläinen O, Lehtimäki K, Laitinen T, Vartiainen N, Vitek MP.

J Neuropathol Exp Neurol. 2014 Aug;73(8):752-69. doi: 10.1097/NEN.0000000000000094.

25.

β-amyloid deposition is shifted to the vasculature and memory impairment is exacerbated when hyperhomocysteinemia is induced in APP/PS1 transgenic mice.

Sudduth TL, Weekman EM, Brothers HM, Braun K, Wilcock DM.

Alzheimers Res Ther. 2014 Jun 9;6(3):32. doi: 10.1186/alzrt262. eCollection 2014.

26.

Obesity and diabetes cause cognitive dysfunction in the absence of accelerated β-amyloid deposition in a novel murine model of mixed or vascular dementia.

Niedowicz DM, Reeves VL, Platt TL, Kohler K, Beckett TL, Powell DK, Lee TL, Sexton TR, Song ES, Brewer LD, Latimer CS, Kraner SD, Larson KL, Ozcan S, Norris CM, Hersh LB, Porter NM, Wilcock DM, Murphy MP.

Acta Neuropathol Commun. 2014 Jun 10;2:64. doi: 10.1186/2051-5960-2-64.

27.

Neuroinflammatory phenotypes and their roles in Alzheimer's disease.

Wilcock DM.

Neurodegener Dis. 2014;13(2-3):183-5. doi: 10.1159/000354228. Epub 2013 Sep 6.

PMID:
24021538
28.

Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis.

Wilcock DM, Griffin WS.

J Neuroinflammation. 2013 Jul 16;10:84. doi: 10.1186/1742-2094-10-84. Review.

29.

APOE-ε2 and APOE-ε4 correlate with increased amyloid accumulation in cerebral vasculature.

Nelson PT, Pious NM, Jicha GA, Wilcock DM, Fardo DW, Estus S, Rebeck GW.

J Neuropathol Exp Neurol. 2013 Jul;72(7):708-15. doi: 10.1097/NEN.0b013e31829a25b9.

30.
31.

Induction of hyperhomocysteinemia models vascular dementia by induction of cerebral microhemorrhages and neuroinflammation.

Sudduth TL, Powell DK, Smith CD, Greenstein A, Wilcock DM.

J Cereb Blood Flow Metab. 2013 May;33(5):708-15. doi: 10.1038/jcbfm.2013.1. Epub 2013 Jan 30.

32.

Are inflammatory profiles the key to personalized Alzheimer's treatment?

Brothers HM, Wilcock DM.

Neurodegener Dis Manag. 2013;3(4):343-351.

33.

Neuroinflammatory phenotype in early Alzheimer's disease.

Sudduth TL, Schmitt FA, Nelson PT, Wilcock DM.

Neurobiol Aging. 2013 Apr;34(4):1051-9. doi: 10.1016/j.neurobiolaging.2012.09.012. Epub 2012 Oct 9.

34.

Nitric oxide-mediated regulation of β-amyloid clearance via alterations of MMP-9/TIMP-1.

Ridnour LA, Dhanapal S, Hoos M, Wilson J, Lee J, Cheng RY, Brueggemann EE, Hines HB, Wilcock DM, Vitek MP, Wink DA, Colton CA.

J Neurochem. 2012 Dec;123(5):736-49. doi: 10.1111/jnc.12028. Epub 2012 Oct 25.

35.

A changing perspective on the role of neuroinflammation in Alzheimer's disease.

Wilcock DM.

Int J Alzheimers Dis. 2012;2012:495243. doi: 10.1155/2012/495243. Epub 2012 Jul 15.

36.

Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of Alzheimer's disease-related pathology.

Bachstetter AD, Norris CM, Sompol P, Wilcock DM, Goulding D, Neltner JH, St Clair D, Watterson DM, Van Eldik LJ.

J Neurosci. 2012 Jul 25;32(30):10201-10. doi: 10.1523/JNEUROSCI.1496-12.2012.

37.

Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer's disease.

Wilcock DM.

Curr Gerontol Geriatr Res. 2012;2012:170276. doi: 10.1155/2012/170276. Epub 2012 Feb 21.

38.

Lithium treatment of APPSwDI/NOS2-/- mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype.

Sudduth TL, Wilson JG, Everhart A, Colton CA, Wilcock DM.

PLoS One. 2012;7(2):e31993. doi: 10.1371/journal.pone.0031993. Epub 2012 Feb 9.

39.

Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses.

Wilcock DM, Zhao Q, Morgan D, Gordon MN, Everhart A, Wilson JG, Lee JE, Colton CA.

ASN Neuro. 2011 Nov 30;3(5):249-58. doi: 10.1042/AN20110018.

40.

Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrence.

Wilcock DM, Morgan D, Gordon MN, Taylor TL, Ridnour LA, Wink DA, Colton CA.

J Neuroinflammation. 2011 Sep 9;8:115. doi: 10.1186/1742-2094-8-115.

41.

The usefulness and challenges of transgenic mouse models in the study of Alzheimer's disease.

Wilcock DM.

CNS Neurol Disord Drug Targets. 2010 Aug;9(4):386-94. Review.

PMID:
20522016
42.

Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease.

Dawson HN, Cantillana V, Jansen M, Wang H, Vitek MP, Wilcock DM, Lynch JR, Laskowitz DT.

Neuroscience. 2010 Aug 11;169(1):516-31. doi: 10.1016/j.neuroscience.2010.04.037. Epub 2010 Apr 29.

43.

Assessing activation states in microglia.

Colton C, Wilcock DM.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):174-91. Review.

PMID:
20205642
44.

Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease.

Wilcock DM, Gharkholonarehe N, Van Nostrand WE, Davis J, Vitek MP, Colton CA.

J Neurosci. 2009 Jun 24;29(25):7957-65. doi: 10.1523/JNEUROSCI.1339-09.2009. Erratum in: J Neurosci. 2010 Jan 20;30(3):1197-8.

45.

Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimer's disease.

Wilcock DM, Vitek MP, Colton CA.

Neuroscience. 2009 Mar 31;159(3):1055-69. doi: 10.1016/j.neuroscience.2009.01.023. Epub 2009 Jan 19.

46.

Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice.

Wilcock DM, Colton CA.

CNS Neurol Disord Drug Targets. 2009 Mar;8(1):50-64. Review.

47.

The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP.

Colton CA, Wilcock DM, Wink DA, Davis J, Van Nostrand WE, Vitek MP.

J Alzheimers Dis. 2008 Dec;15(4):571-87. Review.

48.
49.

Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2.

Wilcock DM, Lewis MR, Van Nostrand WE, Davis J, Previti ML, Gharkholonarehe N, Vitek MP, Colton CA.

J Neurosci. 2008 Feb 13;28(7):1537-45. doi: 10.1523/JNEUROSCI.5066-07.2008.

50.

Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice.

Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D.

Nat Protoc. 2006;1(4):1671-9.

PMID:
17487150

Supplemental Content

Loading ...
Support Center